SCT800 Seen as Safe, Effective for Hemophilia A in Phase 3 Trial

SCT800 Seen as Safe, Effective for Hemophilia A in Phase 3 Trial

301263

SCT800 Seen as Safe, Effective for Hemophilia A in Phase 3 Trial

SCT800, a replacement therapy containing a man-made form of clotting factor VIII (FVIII), appears to be safe and effective at treating and preventing bleeds in adolescents and adults with severe hemophilia A, a study has found. The study, “Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A,” was published in the journal Haemophilia by a team of researchers from China. Treatment with…

You must be logged in to read/download the full post.